Trial Profile
A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Bone metastases; Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 08 May 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
- 02 May 2019 This trial has been discontinued in spain according to European Clinical Trials Database record.
- 11 Aug 2016 Planned End Date changed from 1 Aug 2008 to 1 Sep 2008.